title: Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy.
abstract: OBJECTIVE
  Proteomics technologies are well suited for harnessing the immune response to tumor antigens for diagnostic applications as in the case of breast cancer. We previously reported a substantial impact of hormone therapy (HT) on the proteome. Here, we investigated the effect of HT on the immune response toward breast tumor antigens.
  
  
  METHODS
  Plasmas collected 0-10 months prior to diagnosis of ER+ breast cancer from 190 postmenopausal women and 190 controls that participated in the Women's Health Initiative Observational Study were analyzed for the effect of HT on IgG reactivity against arrayed proteins from MCF-7 or SKBR3 breast cancer cell line lysates following extensive fractionation.
  
  
  RESULTS
  HT user cases exhibited significantly reduced autoantibody reactivity against arrayed proteins compared to cases who were Not Current users. An associated reduced level of IL-6 and other immune-related cytokines was observed among HT users relative to nonusers.
  
  
  CONCLUSIONS
  Our findings suggest occurrence of a global altered immune response to breast cancer-derived proteins associated with HT. Thus a full understanding of factors that modulate the immune response is necessary to translate autoantibody panels into clinical applications.
authors: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors: Timothy
authors: T
authors: Chao
authors: Jon J
authors: JJ
authors: Ladd
authors: Ji
authors: J
authors: Qiu
authors: Melissa M
authors: MM
authors: Johnson
authors: Rebecca
authors: R
authors: Israel
authors: Alice
authors: A
authors: Chin
authors: Hong
authors: H
authors: Wang
authors: Ross L
authors: RL
authors: Prentice
authors: Ziding
authors: Z
authors: Feng
authors: Mary L
authors: ML
authors: Disis
authors: Samir
authors: S
authors: Hanash
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis / Q000276:immunology*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001323:Autoantibodies / Q000276:immunology / Q000378:metabolism; D015551:Autoimmunity; D001798:Blood Proteins / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D045744:Cell Line, Tumor; D018925:Chemokines / Q000097:blood; D016207:Cytokines / Q000097:blood; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007165:Immunosuppression Therapy; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D061986:MCF-7 Cells; D040081:Protein Array Analysis; D040901:Proteomics
chemical_list: D000951:Antigens, Neoplasm; D018931:Antineoplastic Agents, Hormonal; D001323:Autoantibodies; D001798:Blood Proteins; D018925:Chemokines; D016207:Cytokines; D007074:Immunoglobulin G; D036341:Intercellular Signaling Peptides and Proteins
references: Cancer Lett. 2009 Oct 18;284(1):80-5
references: 19427114
references: Genome Med. 2009 Apr 29;1(4):47
references: 19402886
references: JAMA. 2003 Oct 1;290(13):1729-38
references: 14519707
references: JAMA. 2006 Apr 12;295(14):1647-57
references: 16609086
references: J Bone Miner Res. 2006 Jun;21(6):817-28
references: 16753012
references: Arch Intern Med. 2008 Nov 10;168(20):2245-53
references: 19001202
references: JAMA. 2003 Jun 25;289(24):3243-53
references: 12824205
references: Proteomics. 2003 Nov;3(11):2200-7
references: 14595819
references: Clin Lab Med. 2009 Mar;29(1):31-46
references: 19389549
references: OMICS. 2011 Jun;15(6):409-18
references: 21568730
references: Breast Cancer Res Treat. 2010 Jun;121(3):539-53
references: 19655245
references: BMC Vet Res. 2011 Oct 21;7:62
references: 22014164
references: Proteomics. 2003 Oct;3(10):1863-73
references: 14625848
references: Transpl Int. 2009 Nov;22(11):1041-50
references: 19624493
references: Genome Med. 2009 Dec 24;1(12):121
references: 20034393
references: Biochem Biophys Res Commun. 2009 Sep 18;387(2):381-6
references: 19607806
references: Proteomics Clin Appl. 2007 May;1(5):494-505
references: 21136701
references: Cancer Sci. 2007 Aug;98(8):1234-40
references: 17506794
references: JAMA. 2002 Jul 17;288(3):321-33
references: 12117397
references: J Biol Chem. 2005 Mar 4;280(9):8260-5
references: 15613481
references: Environ Health Perspect. 2007 Jun;115(6):A297
references: 17589577
references: Clin Cancer Res. 2009 Jul 15;15(14):4733-41
references: 19584157
references: PLoS One. 2009 Nov 19;4(11):e7916
references: 19936259
references: JAMA. 2004 Apr 14;291(14):1701-12
references: 15082697
references: Mol Cell Proteomics. 2008 Feb;7(2):268-81
references: 17916591
references: JAMA. 2003 May 28;289(20):2673-84
references: 12771114
references: PLoS Clin Trials. 2007 Jun 15;2(6):e28
references: 17571161
references: Adv Clin Chem. 2009;47:59-93
references: 19634777
references: Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):134-9
references: 21037107
references: Hypertension. 2003 Oct;42(4):657-63
references: 12913055
references: Gynecol Endocrinol. 2011 Oct;27(10):800-6
references: 21879795
references: BMC Med. 2006 Jun 30;4:16
references: 16813654
references: Horm Cancer. 2010 Oct;1(5):229-44
references: 21258428
references: Circulation. 2006 May 23;113(20):2425-34
references: 16702472
references: J Clin Endocrinol Metab. 2000 Mar;85(3):1340-4
references: 10720088
references: J Clin Oncol. 2008 Nov 1;26(31):5060-6
references: 18794547
references: J Immunol Methods. 2005 Apr;299(1-2):129-38
references: 15914197
references: J Thromb Haemost. 2008 Jun;6(6):928-34
references: 18394014
references: Cancer Res. 2004 Aug 1;64(15):5504-10
references: 15289361
references: Proteomics. 2003 Nov;3(11):2108-15
references: 14595809
references: Scand J Immunol. 2008 Dec;68(6):661-7
references: 19086108